Change to classification of MDMA and psilocybin to enable prescribing by authorised psychiatrists

This webinar will address the recent announcement by the Therapeutic Goods Administration (TGA) that medicines containing psilocybin and MDMA will be classified as Schedule 8 (controlled drug) in the Poisons Standard for specific conditions when prescribed by a psychiatrist under the Authorised Prescriber scheme.

Background

From 1 July 2023, the TGA will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression. They will only be able to be prescribed by authorised psychiatrists who have been approved under the Authorised Prescriber scheme and approved by a Human Research Ethics Committee.

Webinar details

When: Wednesday, 1 March 2023

Where: Online

Time: 4.30pm - 5.30pm AEDT

Register for webinar